Dr. Florian Kuchenbauer and Dr. François Bénard receive CPDC funds for developing an LAT1-targeting PET tracer for imaging cancer

BC Cancer's Dr. Florian Kuchenbauer and Dr. François Bénard, in collaboration with TRIUMF Innovations and led by Dr. Robert Britton from Simon Fraser University, have secured a grant from the Centre for Probe Development and Commercialization (CPDC)  to conduct ground-breaking research in cancer imaging.

Kwangjin Park (Hoodless Lab) awarded Canadian Institutes of Health Research Postdoctoral Fellowship Award

Kwangjin Park (Hoodless Lab) has been awarded the Canadian Institutes of Health Research 2022 Postdoctoral Fellowship Award for the project titled, "Roles of the Lysine Methyl Transferase (KMT) 2D in hepatocyte cell identity and hepatocellular carcinoma (HCC) progression." Read the announcement here.

Research reveals insights into lymphoma relapse and treatment response

A recent study conducted by researchers at BC Cancer has shed light on the cause behind the different outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who experience a relapse of their disease. The study, led by Dr. Laura Hilton, staff scientist at BC Cancer’s Centre for Lymphoid Cancer (CLC), and Dr. David Scott, clinical director of the CLC, aimed to understand the molecular characteristics of the initial diagnostic and relapse tumour samples of patients with DLBCL.

New Hire Focus: Dr. Carol Chen is unravelling the mysteries of high-grade gliomas

Dr. Carol Chen is dedicated to understanding the complexities and finding innovative solutions to high-grade gliomas (HGGs); a particularly aggressive form of brain cancer affecting children and young adults. The new BC Cancer scientist, who joined the Terry Fox Laboratory in 2023, is focused on understanding how mutations in certain proteins, called histones or histone-modifying enzymes, contribute to the development of HGGs.

Back to top